News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trigemina Attracts $4.5 Million Funding From Current Investors and Chilean Government Grant


6/17/2013 8:53:05 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MORAGA, Calif., June 17, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced the completion of a $4.5 million Series A-1 financing. The financing round was led by existing Chilean-based investor Aurus, through its Aurus Bios Fund, and is supplemented by a grant awarded by the government of Chile. Proceeds for the Series A-1 round will be used to fund the completion of the Phase II TRIG-05 clinical trial evaluating the Company's lead drug candidate, TI-001, an intranasal oxytocin therapy, for the treatment of chronic migraine.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES